You are viewing an expired study
This study is not currently recruiting Study Participants on If you would like to find active studies please search for clinical trials

Phoenix, Arizona

  • Lumbar Disc Disease


The purpose of this study is to evaluate the safety and efficacy of SI-6603(Condoliase) in patients with lumbar disc herniation.


Inclusion Criteria: - Patients with lumbar disc herniation (L1-L2, L2-L3, L3-L4, L4-L5 or L5-S1) as assessed by MRI and clinical symptoms corresponding to position of the impaired nerve root. - Patients assessed as positive in the Femoral Nerve Stretching (FNS) test for L1-L2, L2-L3, or L3-L4 and Straight Leg Raising (SLR) test. - Patients with sciatica in either leg. - Patients with no improvement from conservative treatment Exclusion Criteria: - Patients who have 2 or more lumbar disc herniations as assessed by MRI. - Patients in whom a rupture into the posterior longitudinal ligament is identified by MRI. - Patients who have undergone lumbar operation, or lumbar percutaneous nucleotomy or lumbar intradiscal therapies

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:

Brief Title:

A Study of SI-6603 in Patients With Lumbar Disc Herniation

Official Title:

A Multicenter, Open-label Study of SI 6603 in Patients With Lumbar Disc Herniation (Phase III)

Overall Status:


Study Phase:

Phase 3



Minimum Age:

30 Years

Maximum Age:

70 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Seikagaku Corporation

Oversight Authority:

  • United States: Food and Drug Administration
  • Spain: Spanish Agency of Medicines

Reasons Why Stopped:

Study Type:


Study Design:

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Study Dates

Start Date:March 2015
Completion Date:February 2018
Completion Type:Actual
Primary Completion Date:February 2018
Primary Completion Type:Actual
Verification Date:March 2019
Last Changed Date:March 20, 2019
First Received Date:April 6, 2015

Study Outcomes

Outcome Type:Secondary Outcome
Measure:Leg pain as assessed by a Visual Analog Scale (VAS)
Time Frame:26 weeks
Safety Issues:False
Description:Assessed by a Visual Analog Scale (VAS)
Outcome Type:Primary Outcome
Measure:Evaluate the safety of a single-dose intervertebral disc injection of SI-6603 in patients with lumbar disc herniation.
Time Frame:26 weeks
Safety Issues:False
Description:The occurence of Adverse Events as a measure to evaluate the safety of a single-dose of SI-6603

Study Interventions

Intervention Type:Drug
Description:1.25 U, intradiscal injection, one time
Arm Name:SI-6603

Study Arms

Study Arm Type:Experimental
Arm Name:SI-6603
Description:SI-6603: SI-6603 is administrated into the nucleus pulposus of the intervertebral disc

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Seikagaku Corporation

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source:

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.